{'fraction_non_alphanumeric': 0.03492333901192504, 'fraction_numerical': 0.015332197614991482, 'mean_word_length': 4.703883495145631, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increased c-met Expression During Ductal β Cell Neogenesis in Experimental Autoimmune Diabetes

Abstract C-met immunoreactivity and its co-expression with duct-associated insulin were evaluated in pancreata of non-obese diabetic (NOD) and low-dose streptozotocin (Id-STZ) mice. Diabetic NOD and non-diabetic NOD at the age of 4–8, 15–22 and 30–41 weeks and Balbk mice at the same age intervals were studied. Ld-STZ mice were studied at day 12 and 24 after STZ administration. A stronger ductal c-met immunoreactivity and a significantly higher number of c-met positive ducts were found in diabetic NOD vs both non-diabetic NOD and Balbk mice of comparable age. In non-diabetic NOD, the ductal c-met immunoreactivity progressively increased with age and was significantly higher than controls. In Id-STZ mice a significantly increased ductal c-met immunoreactivity was detected both at day 12 and 24 vs untreated mice. C-met positive ductal cells were also positive for insulin although insulin positive c-met negative ducts were present. This study showed an increased c-met expression and the co-expression of c-met and duct-associated insulin, in both NOD and Id-STZ mice.